[go: up one dir, main page]

CN110051830A - A kind of protease nexin II KPI protein mutant application - Google Patents

A kind of protease nexin II KPI protein mutant application Download PDF

Info

Publication number
CN110051830A
CN110051830A CN201910194270.3A CN201910194270A CN110051830A CN 110051830 A CN110051830 A CN 110051830A CN 201910194270 A CN201910194270 A CN 201910194270A CN 110051830 A CN110051830 A CN 110051830A
Authority
CN
China
Prior art keywords
kpi
protease nexin
mutant
hemophilia
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910194270.3A
Other languages
Chinese (zh)
Inventor
许晓倩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ningbo baishening Biomedical Technology Co.,Ltd.
Original Assignee
Suzhou Xinning Biomedical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Xinning Biomedical Technology Co Ltd filed Critical Suzhou Xinning Biomedical Technology Co Ltd
Priority to CN201910194270.3A priority Critical patent/CN110051830A/en
Publication of CN110051830A publication Critical patent/CN110051830A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a kind of protease nexin II KPI protein mutant and derivative, analog or its application for forming segment, be used to prepare treatment and acquired Hemophilia and have the hemophilia related disease of mortifier generation or the drug of illness.Present invention can apply to the preparations of hemorrhagic disease drug, especially have the haemophiliachemophiliac related drugs of mortifier, have a good application prospect.

Description

A kind of protease nexin II KPI protein mutant application
Technical field
The invention belongs to hemorrhage therapy field, in particular to a kind of protease nexin II KPI protein mutant And its derivative, analog or its application for forming segment.
Background technique
Hemophilia A and B are the hereditary hemorrhagic diseases due to caused by blood coagulation factor VIII (FVIII) or IX (FIX) defect, Disease incidence is 1/5000 and 1/2000 in males, shows as coagulation disorders on patient clinical, may occur in which spontaneous flesh Meat hemotoncus and articular cavity bleeding etc..FVIII/FIX replacement therapy is currently the only effective treatment means.With biotechnology Development, the FVIII/FIX of genetic recombination, the FVIII/FIX for having gradually replaced blood plasma or blood plasma source become replacement therapy Primary formulation.FVIII Half-life in vivo is only less than 12 hours, and FIX also only has 24 hours or so, in order to maintain enough blood plasma Concentration is to prevent bleeding, and patient needs to inject weekly 2~3 times, and somewhat expensive, the western countries such as U.S. in 2011 are annual according to statistics FVIII formulations sold volume be more than 5,200,000,000 dollars, it is contemplated that 2016 can be more than 7,000,000,000 dollars.Although replacement therapy can be effectively pre- Bleeding caused by anti-and treatment FVIII/FIX defect, but have 30% haemophiliac can generate over the course for the treatment of it is anti- FVIII antibody, small part hemophilia B patient can also generate FIX antibody, replacement therapy caused to fail, it has to use high dose The drug that FVIII immune induction is resistance to treated or application is including proconvertin (FVIIa) of activation etc. controls bleeding, Medical expense is costly.It is more than 1,600,000,000 dollars to treat generation that medical insurance department, American-European countries needs ancillary cost every year The haemophiliac of FVIII/FIX mortifier.Generation and the direct phase of dosage in FVIII preparation replacement therapy of FVIII antibody It closes, replacement therapy is because of the high dose carried out under the bleedings emergencies such as operation, wound to children haemophiliac for the first time When FVIII hemostatic treatment, the probability that FVIII mortifier generates is dramatically increased, and dosage is higher, and treatment time-histories is longer, and FVIII inhibits Object is more easy to produce, and the probability that mortifier generates when dosage is higher than 35IU/Kg is less than 2.4 times of 35IU/Kg treatment group.Blood Friendly disease bleeding performance in blood plasma FVIII or FIX activity it is related, however, patient similar in coagulation factor activity is horizontal out Blood severity is still different.Studies have found that proposing, the genetic risk factors and hemophilia of pro-thrombotic coexist may Improve the bleeding severity of haemophiliac.Clot strength has the quantity of fibrin ferment caused by Coagulation test related, blood coagulation Enzyme can also convert its work for PROTEIN C under the auxiliary of the thrombomodulin on endothelial cell other than having the function of to promote to coagulate The aPC of change form.For the latter using protein s as co-factor, catalytic pyrolysis simultaneously inactivates FVa and FVIIIa, limits the model of Coagulation test It encloses and intensity.In addition to heredity PC lacks, labile factor (FV) Leiden mutation is because it has resistance to the cracking of aPC Effect, is all the genetic risk factors of thrombophilia.Haemophiliac exists simultaneously FV Leiden or PC defect, bleeding It shows slight compared with other patients.
Protease nexin II KPI be a kind of two 6,500Da of molecule peptide molecule, be protease nexin The constituent of II albumen, is expressed in the Various Tissues of human body, such as nerve cell, blood platelet etc..protease nexin II KPI polypeptide chain be made of 57 amino acid residues.Protease nexin II KPI albumen physiological function be specificity Activation plasma thromboplastin antecedent mortifier.Protease nexin II KPI be all serpin suppression Peptase is homologous in structure.Aprotinin passes through its height to fibrinolysin (Ki~1nM) and kallikrein (Ki~30~36nM) Specific inhibitory activity is spent to inhibit fibrin degradation, while Aprotinin is also with other albumen of relatively low activity suppression Enzyme, it is with medium inhibitory activity but compound to FVIIa/TF to FXIa (1.1uM) and activated protein C (Ki~1.1~2.6uM) Object (Ki > 10uM), FXa (Ki > 10uM) or fibrin ferment (Ki~27~61uM) have little effect.Aprotinin is in openheart surgery It can dramatically reduction amount of bleeding, reduce the blood transfusion needs in such operation.But Aprotinin derives from animal tissue's (mainly ox lung It is dirty), it is possible to create the adverse reactions such as allergy are transformed by homologous protein, by protease nexin II in human body in KPI Amino acid substitution changes its enzyme inhibition, thus the blood coagulation enhancing effect similar with Aprotinin.protease nexin II\ KPI mutant R15K/M17K and R15K/M17R inhibits the affinity of object plasma thromboplastin antecedent to be remarkably decreased its physiology, by 2nM Increasing is 3081 and 707nM, but is reduced to 8nM or so by 200nM to the inhibitory activity of fibrinolysin, has prompted its anti-fibrinolysis activity Enhancing.Meanwhile the inhibiting effect of aPC is also enhanced.
Summary of the invention
Technical problem to be solved by the invention is to provide a kind of protease nexin II KPI mutant (R15K/ M17K) and its derivative, analog or its application for forming segment, the R15K/M17K mutant have the work of Activated protein C resistance Property and inhibit Fibrinolysis characteristic, can by weaken body anticoagulation, enhancing independent of plasma thromboplastin component (FIX)/ The Coagulation test of blood coagulation factor VIII (FVIII) promotes body entirety coagulation function, to correct caused by deficiency of coagulation factors Coagulation function defect can be applied to the preparation of hemorrhagic disease drug.
The present invention provides a kind of protease nexin II KPI mutant (R15K/M17K) and derivative, analog Or its application for forming segment, be used to prepare treatment and acquired Hemophilia and have mortifier generation hemophilia related disease or The drug of illness.
The related disease or illness are deficiency of coagulation factors, and with coagulation factor antibody or may inhibit produce simultaneously It is raw.
The protease nexin II KPI mutant (R15K/M17K) amino acid sequence such as SEQ ID NO:1 institute Show.
The protease nexin II KPI mutant (R15K/M17K) merge to be formed with other fusion proteins Protease nexin II KPI mutant (R15K/M17K) fusion protein.
The fusion protein is human albumin, 1 antitrypsin of immunoglobulin Fc, transferrins or alpha.
The present invention also provides a kind of protease nexin II KPI mutant (R15K/M17K) albumen preparation side Method includes the following steps:
(1) by protease nexin II KPI mutant (R15K/M17K) gene be connected into carrier, obtain recombination carry Body；
(2) above-mentioned recombinant vector is converted into host cell, obtains expression recombinant cell clone, cell can be mammal Cell, insect cell, fungi or bacterium；
(3) the above-mentioned recombinant cell clone of continuously perfused culture or fungi bacterial fermentation in serum free medium, induction weight The expression of group Aprotinin；
(4) isolate and purify, filter, last filling, freeze-drying, obtain expressed protease nexin II KPI mutation Body (R15K/M17K) albumen.
Purifying in the step (4) includes just pure and mild consummate.
The present invention provide comprising protease nexin II KPI mutant (R15K/M17K) (recombination or animal tissue Purification) drug prevent and/or treat disease, wherein the disease mainly includes hemorrhagic disease or various originals for diagnosing The bleeding because caused by；Wherein, most probable hemorrhagic disease is hemophilia A and B, i.e., due to hereditary coagulation factors VIII or IX Hemorrhagic disease caused by lacking, and including the hemophilia A and B that wherein there is inhibiting antibody to generate or the day after tomorrow because of mortifier Acquired blood coagulation factor VIII or IX caused by generating lack；And other hemorrhagic diseases using bypass preparation, such as newly Raw youngster's blood coagulation disorders；Serious liver diseases；High risk operation；Traumatic blood loss；Bone-marrow transplantation；Thrombopenia and blood are small Plate dysfunction；Take orally anticoagulant urgent reverse；The defect of congenital factor V, VII, X and XI；Von Willebrand disease, and Acquired von Willebrand Disease caused by vWF ELISA mortifier, and largely damages related blood loss, cerebral hemorrhage, Dysfunction of platelet.
Beneficial effect
Protease nexin II in the present invention KPI mutant (R15K/M17K) there is the activity of Activated protein C resistance With the characteristic for inhibiting Fibrinolysis, by inhibiting body anticoagulating active, correct because of clotting defect caused by deficiency of coagulation factors and Bleeding performance, therefore by promoting blood solidifying independent of plasma thromboplastin component (FIX)/blood coagulation factor VIII (FVIII) mechanism Collection promotes body entirety coagulation function, plays anastalsis, therefore can be applied to the preparation of hemorrhagic disease drug, especially right There is the preparation of the related drugs of the Treatment of Hemophilia of mortifier, due to the transformation that it is the intrinsic albumen of human body, compared with animal-type Protein immunization is small, highly-safe, has good treatment use prospect.
Detailed description of the invention
Fig. 1 be protease nexin II KPI mutant (R15K/M17K) inhibit activated protein C effect diagram；
Fig. 2A and B be protease nexin II KPI mutant (R15K/M17K) correct hemophilia A and have a mortifier Blood coagulation generates the schematic diagram of defect in existing hemophilia A plasma；
Fig. 3 be protease nexin II KPI mutant (R15K/M17K) correct hemophilia A mouse dock amount of bleeding Schematic diagram；
Fig. 4 be protease nexin II KPI mutant (R15K/M17K) promote hemophilia A blood in the micro- damage of blood vessel Blood clotting schematic diagram in wound.
Specific embodiment
Present invention will be further explained below with reference to specific examples.It should be understood that these embodiments are merely to illustrate the present invention Rather than it limits the scope of the invention.In addition, it should also be understood that, after reading the content taught by the present invention, those skilled in the art Member can make various changes or modifications the present invention, and such equivalent forms equally fall within the application the appended claims and limited Range.
Embodiment 1
Protease nexin II KPI mutant (R15K/M17K) to the inhibiting effect of PROTEIN C
In purifying protein system, by the protease nexin II of various concentration KPI mutant (R15K/M17K) with Activated protein C reacts jointly, and by aPC specificity luminous substrate detection by protease nexin II KPI mutant (R15K/M17K) inhibit after remaining aPC activity, the results show that with protease nexin II KPI mutant (R15K/M17K) concentration increases, and the activity of aPC gradually decreases, protease nexin II KPI mutant (R15K/M17K) To the inhibitory activity (IC50~1uM) (Fig. 1) with moderate of aPC.
Embodiment 2
Protease nexin II KPI mutant (R15K/M17K) correct hemophilia A, B patients blood plasma and have mortifier Hemophilia A patients' blood plasma in fibrin ferment generate defect
Fibrin ferment generates test (thrombin generation test, TGT): it is raw to can be used for assessing fibrin ferment in blood plasma It is a kind of whole coagulation function test of analogue body intravascular coagulation condition at ability, has reacted the summation effect of blood coagulation and anticoagulation system It answers.Blood plasma Coagulation test is to obtain starting activator (containing tissue factor and phosphatide) is added afterwards, and fibrin ferment is generated by specificity Fluorogenic substrate detection, is changed by FLUOROSKAN Fluorescent reader dynamic monitoring fluorescence intensity, and raw using specific fibrin ferment At experiment software by fluorescence signal conversion digital signal, fibrin ferment formation curve is drawn.It can be with from several parameters of formation curve Fibrin ferment generative capacity: (1) delay time (lag time) is evaluated, i.e., is taken since reaction to generating fibrin ferment Between；(2) peak value (peak), that is, the fibrin ferment maximum generated；(3) peak time (time to peak, ttpeak), i.e., from anti- The time required to should starting to fibrin ferment reach to peak value；(4) fibrin ferment generate potentiality (endogenous thrombin potential, ETP), i.e., area under fibrin ferment formation curve, reaction fibrin ferment generate total amount.When the thrombus tune that solubility is added in Coagulation test After saving plain (TM), PROTEIN C activation inhibits fibrin ferment to generate, can react influence of the anticoagulation system to whole blood coagulation.
Containing/without containing mortifier haemophilic plasmas in be added protease nexin II KPI mutant (R15K/M17K) (30uM) starts Coagulation test TF is added, has a certain amount of fibrin ferment to generate in blood plasma, but as addition TM After activated protein C, anticoagulation system plays a role, almost without progress fibrin ferment generation.When protease nexin II KPI mutation After reaction system is added in body (R15K/M17K), the inhibiting effect that PROTEIN C generates fibrin ferment can be turned with Partial Inverse, remain blood The ability that fibrin ferment generates in slurry.Compared with the effect in the haemophilic plasmas of unrestraint object (Fig. 2A), protease nexin II this anti-PROTEIN C of KPI mutant (R15K/M17K) ability that promotes fibrin ferment to generate be not inhibited the influence (Fig. 2 B) of object.
Embodiment 3
Protease nexin II KPI mutant (R15K/M17K) improve hemophilia mouse dock bleeding phenotype
By protease nexin II KPI mutant (R15K/M17K) enter through tail vein injection 4-8 weeks hemophilia Make in blood plasma in Mice Mice model protease nexin II KPI mutant (R15K/M17K) Cmax reach 30uM.Together When injecting normal saline as negative control, (Cmax is that normal 100%) is positive control to blood coagulation factor VIII.Mouse fiber crops It is to dock at 2mm, and tail is overhang and is placed in room temperature PBS buffer solution in rat-tail end diameter after liquor-saturated, timing 10min, detection examination The concentration of hemoglobin in pipe, according to the amount of bleeding of hemoglobin content measuring and calculating docking, with the hemophilia mouse bleeding of saline treatment Amount is control (100%) (Fig. 3).Protease nexin II KPI mutant (R15K/M17K) to substantially reduce hemophilia A small The bleeding phenotype of mouse, lacking caused clotting defect to blood coagulation factor VIII has improvement result, when Cmax is 30uM The anastalsis played can be similar to the haemostatic effect of 100% blood coagulation factor VIII, similar with the amount of bleeding of normal mouse.
Embodiment 4
Protease nexin II KPI mutant (R15K/M17K) promote hemophilia A blood in blood vessel micro-damage Blood clotting
After tail vein injection fluorescent marker blood platelet, hemophilia mouse mesenteric microvessels are separated under microscope, are swashed Light injury local vascular observes platelet aggregation.Protease nexin II KPI mutant (R15K/M17K) Cmax reach (Cmax is that normal 100%) is similar to the ability of blood clotting, is shown very strong non-solidifying with blood coagulation factor VIII when to 30uM The rush that blood factor VIII is relied on coagulates ability (Fig. 4).
SEQUENCE LISTING
<110>Suzhou Xin Ning biological medicine Science and Technology Ltd.
<120>a kind of application of protease nexin II KPI protein mutant
<130> 1
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 57
<212> PRT
<213>artificial sequence
<400> 1
Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Lys Ala Lys Ile
1 5 10 15
Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe
20 25 30
Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr
35 40 45
Cys Met Ala Val Cys Gly Ser Ala Ile
50 55

Claims (5)

1. a kind of protease nexin II KPI mutant, derivative, analog or its form segment application, feature It is: being used to prepare treatment and acquired Hemophilia and have the hemophilia related disease of mortifier generation or the drug of illness.
2. application according to claim 1, it is characterised in that: the related disease or illness are to lack with coagulation factor Antibody or mortifier.
3. application according to claim 1, it is characterised in that: the protease nexin II KPI mutant ammonia Base acid sequence is as shown in SEQ ID NO:1.
4. application according to claim 1, it is characterised in that: the protease nexin II KPI mutant and its His fusion protein merge to be formed protease nexin II KPI mutant fusion protein.
5. application according to claim 3, it is characterised in that: the fusion protein be human albumin, immunoglobulin Fc, 1 antitrypsin of transferrins or alpha.
CN201910194270.3A 2019-03-14 2019-03-14 A kind of protease nexin II KPI protein mutant application Pending CN110051830A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910194270.3A CN110051830A (en) 2019-03-14 2019-03-14 A kind of protease nexin II KPI protein mutant application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910194270.3A CN110051830A (en) 2019-03-14 2019-03-14 A kind of protease nexin II KPI protein mutant application

Publications (1)

Publication Number Publication Date
CN110051830A true CN110051830A (en) 2019-07-26

Family

ID=67317118

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910194270.3A Pending CN110051830A (en) 2019-03-14 2019-03-14 A kind of protease nexin II KPI protein mutant application

Country Status (1)

Country Link
CN (1) CN110051830A (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) * 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1996035788A2 (en) * 1995-05-08 1996-11-14 Scios, Inc. Kunitz type protease inhibitors
WO1999063090A2 (en) * 1998-06-03 1999-12-09 Scios, Inc. Protease inhibitor peptides
CN1882357A (en) * 2003-11-20 2006-12-20 诺和诺德医疗保健公司 Therapeutic use of factor XI
US20090004175A1 (en) * 2004-07-16 2009-01-01 Novo Nordick Health Care A/G Methods for Optimizing Forming Vlla-Based Hemostatic Treatment
WO2015002611A1 (en) * 2013-07-01 2015-01-08 National University Of Singapore Compositions and methods for inhibiting thrombogenesis
US20160311887A1 (en) * 2013-12-13 2016-10-27 Cambridge Enterprise Limited Modified serpins for the treatment of bleeding disorders
CN109316599A (en) * 2018-08-24 2019-02-12 上海交通大学医学院附属瑞金医院 Application of aprotinin or mutant, derivative, analogue or constituent fragment thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) * 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1996035788A2 (en) * 1995-05-08 1996-11-14 Scios, Inc. Kunitz type protease inhibitors
WO1999063090A2 (en) * 1998-06-03 1999-12-09 Scios, Inc. Protease inhibitor peptides
CN1882357A (en) * 2003-11-20 2006-12-20 诺和诺德医疗保健公司 Therapeutic use of factor XI
US20090004175A1 (en) * 2004-07-16 2009-01-01 Novo Nordick Health Care A/G Methods for Optimizing Forming Vlla-Based Hemostatic Treatment
WO2015002611A1 (en) * 2013-07-01 2015-01-08 National University Of Singapore Compositions and methods for inhibiting thrombogenesis
US20160311887A1 (en) * 2013-12-13 2016-10-27 Cambridge Enterprise Limited Modified serpins for the treatment of bleeding disorders
CN109316599A (en) * 2018-08-24 2019-02-12 上海交通大学医学院附属瑞金医院 Application of aprotinin or mutant, derivative, analogue or constituent fragment thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NAVANEETHAM,D等: ""Chain B, Crystal Structure Of The Catalytic Domain Of Coagulation Factor Xi In Complex With Kunitz Protease Inhibitor Domain Of Protease Nexin Ii"", 《NCBI PROTEIN》 *
NAVANEETHAM等: ""P1 and P2 " site mutations convert protease nexin-2 from a factor XIa inhibitor to a plasmin inhibitor"", 《JOURNAL OF BIOCHEMISTRY》 *
贺石林等: "内在凝血途径的接触激活――抗血栓形成研究的新靶点", 《血栓与止血学》 *

Similar Documents

Publication Publication Date Title
Staton et al. The role of fibrinogen and related fragments in tumour angiogenesis and metastasis
JP5037331B2 (en) Factor IXA for the treatment of bleeding disorders
JP6514893B2 (en) Compositions and methods for modulating hemostasis
ES2343681T3 (en) FACTOR INTERACTION ANTAGONISTS VIII WITH A PROTEIN RELATED TO LOW DENSITY LIPOPROTEIN RECEPTOR.
Altieri et al. Structurally homologous ligand binding of integrin Mac-1 and viral glycoprotein C receptors
CN108220274B (en) Preparation and application of high-activity coagulation factor XI mutant, gene therapy/editing vector and recombinant/fusion protein thereof
US20180055913A1 (en) Recombinant collagen iv surrogates and uses thereof
CN109260462B (en) Application of a prothrombin mutant protein and its encoding nucleic acid
JP2009528293A (en) Compositions and methods for regulating hemostasis using various forms of activated factor V
EP3225252A1 (en) Treatment of bleeding with low half-life fibrinogen
CA2709337A1 (en) Haemostasis- modulating compositions and uses therefor
JP4701355B2 (en) Prothrombin activating protein
CN110051830A (en) A kind of protease nexin II KPI protein mutant application
FR2913020A1 (en) Human factor VIII variants useful for treating hemophilia A have one or more amino acid substitutions in defined positions
RU2006115783A (en) THERAPEUTIC APPLICATION OF FACTOR XI
CN109316599A (en) Application of aprotinin or mutant, derivative, analogue or constituent fragment thereof
CN108517009A (en) Sj13 polypeptides and its application in preparing antithrombotic reagent
CN108210893A (en) Prevent and treat drug of kidney fibrosis and application thereof
JP2023505208A (en) Compositions and methods for modulating the function of Factor VIII
CN1314915A (en) Novel sugar chain-bonded thrombomodulin-like peptide
CN119684441A (en) A derivative polypeptide PM6 and its application in anti-thrombosis
WO1995018829A1 (en) Factor viii derivatives
JPH10504310A (en) How to treat a patient with a biologically active compound
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality
CN113301907A (en) Drug for treating and/or improving sepsis associated with blood coagulation disorder

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200108

Address after: No. 16, qiaotouhu street, middle Qiaojing Road, Ninghai County, Ningbo City, Zhejiang Province

Applicant after: Ningbo baishening Biomedical Technology Co.,Ltd.

Address before: 215400 LA14, Building 11, University Science Park, No. 20 Jianxiong Road, Taicang Science and Education New Town, Suzhou City, Jiangsu Province

Applicant before: Suzhou Xinning Biomedical Technology Co.,Ltd.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190726